Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand

Background: In early 2021, the Ministry of Public Health of Thailand announced heterologous regimens for COVID-19 vaccines using CoronaVac as the first dose followed by ChAdOx1 nCoV-19 at 3 weeks apart. Priority was given to individuals above 60 years old and those who had seven underlying condition...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Kriangkrai Chawansuntati, Supachai Sakkhachornphop, Sayamon Hongjaisee, Saranta Freeouf, Patumrat Sripan, Nattaya Nusartsang, Romanee Chaiwarith, Tavitiya Sudjaritruk, Khuanchai Supparatpinyo, Jiraprapa Wipasa
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2024-06-01
Edice:	Vaccine: X
Témata:	Coronavirus disease (COVID-19) CoronaVac ChAdOx1 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing antibodies
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2590136224000482
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!